 SOUTH SAN FRANCISCO, Calif., May 16, 2022 GLOBE NEWSWIRE -- Imago BioSciences, Inc. Imago Nasdaq: IMGO, a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms MPNs, today announced that Hugh Young Rienhoff, Jr., M.D., Imagos Chief Executive Officer, will participate in three upcoming investor conferences. 